LRRK2 and Parkinsonism: Taken together, these observations suggest that both knockdown and pharmacologic models are biologically comparable and that reduced or suppressed LRRK2 expression by pharmacologic or gene LRRK2 blockage might delay or prevent motor symptoms in persons at risk of suffering Parkinsonism by impeding structural or functional impairment (= neurodegeneration) in the DAergic neurons.